Dhar, S., Daniel, W
No step therapy requirements
The biggest catalyst will be progress with its leading candidate, subcutaneous VK2735
Drucker, who is an endocrinologist, Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology and professor of medicine in the division of endocrinology at University of Toronto and has a laboratory based in the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, said GLP-1s have gone from scientists questioning why anyone would want to use an injectable sulfonylurea to a class of drugs that have numerous benefits, including: reductions in albuminuria, atherosclerosis, body weight, blood pressure, cell death, fibrosis, glucose, gut motility, inflammation, oxidative stress, platelet aggregation, postprandial lipemia and thrombosis
This makes it a useful option for individuals who are looking to support their training and fitness goals by improving muscle efficiency and cell growth